80 related articles for article (PubMed ID: 16885561)
1. Lineage-specific hematopoietic growth factors.
Ferretti G; Papaldo P; Cognetti F
N Engl J Med; 2006 Aug; 355(5):526; author reply 527. PubMed ID: 16885561
[No Abstract] [Full Text] [Related]
2. Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?
Di Cosimo S; Ferretti G; Papaldo P; Carlini P; Fabi A; Ruggeri EM; Alimonti A; Nardoni C; Cognetti F
Ann Oncol; 2005 Jul; 16(7):1209-10. PubMed ID: 15857847
[No Abstract] [Full Text] [Related]
3. Can granulocyte-colony stimulating factor worsen anemia?
Dang C; Hudis C
J Clin Oncol; 2006 Jul; 24(19):2985-6. PubMed ID: 16769981
[No Abstract] [Full Text] [Related]
4. [Cancer of the breast in young women: should chemotherapy be intensified?].
Piccart MJ
Pathol Biol (Paris); 1992 Nov; 39(9):843-4. PubMed ID: 1371604
[No Abstract] [Full Text] [Related]
5. Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?
Papaldo P; Ferretti G; Di Cosimo S; Giannarelli D; Marolla P; Lopez M; Cortesi E; Antimi M; Terzoli E; Carlini P; Vici P; Botti C; Di Lauro L; Naso G; Nisticò C; Mottolese M; Di Filippo F; Ruggeri EM; Ceribelli A; Cognetti F
J Clin Oncol; 2006 Jul; 24(19):3048-55. PubMed ID: 16769988
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
[TBL] [Abstract][Full Text] [Related]
7. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
Tamura K
Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
[No Abstract] [Full Text] [Related]
8. Acute myeloid leukaemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Ferretti G; Papaldo P
Breast Cancer Res Treat; 2008 May; 109(1):187-8. PubMed ID: 17616805
[No Abstract] [Full Text] [Related]
9. Chronic myeloid leukemia following cyclophosphamide-containing chemotherapy in a breast cancer patient.
Porta C; Casagranda I; Semino G; Moroni M; Ratto C
Haematologica; 1993; 78(1):56-7. PubMed ID: 8387943
[No Abstract] [Full Text] [Related]
10. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients.
Filip S; Vanásek J; Bláha M; Mericka P; Vávrová J; Podzimek K
Neoplasma; 1999; 46(3):166-72. PubMed ID: 10613592
[TBL] [Abstract][Full Text] [Related]
11. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
13. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
[TBL] [Abstract][Full Text] [Related]
14. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
Ottosson S; Magnusson K; Hultborn R
Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
[TBL] [Abstract][Full Text] [Related]
15. An unusual cause of a marked leukocytosis and an abnormal blood film.
Hargreaves T; Varey M; Kataria U; Renton B
Br J Hosp Med (Lond); 2015 Mar; 76(3):174-5. PubMed ID: 25761812
[No Abstract] [Full Text] [Related]
16. Secondary leukemia after autologous peripheral blood progenitor cell transplantation for breast cancer.
Sica S; Salutari P; Ciarli M; Piccirillo N; Laurenti L; Menichella G; Leone G
Leukemia; 1997 Nov; 11(11):1990-2. PubMed ID: 9369440
[No Abstract] [Full Text] [Related]
17. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Kröger N; Damon L; Zander AR; Wandt H; Derigs G; Ferrante P; Demirer T; Rosti G; ; ;
Bone Marrow Transplant; 2003 Dec; 32(12):1153-7. PubMed ID: 14647269
[TBL] [Abstract][Full Text] [Related]
18. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
Polyzos A; Malamos N; Boukovinas I; Adamou A; Ziras N; Kalbakis K; Kakolyris S; Syrigos K; Papakotoulas P; Kouroussis C; Karvounis N; Vamvakas L; Christophyllakis C; Athanasiadis A; Varthalitis I; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2010 Jan; 119(1):95-104. PubMed ID: 19636702
[TBL] [Abstract][Full Text] [Related]
19. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
[TBL] [Abstract][Full Text] [Related]
20. Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor.
Tatetsu H; Matsuno F; Takatsu N; Miyake H; Hoshino K; Nosaka K; Horikawa K; Hata H; Mitsuya H; Asou N
Leuk Res; 2009 Jan; 33(1):197-200. PubMed ID: 18472159
[No Abstract] [Full Text] [Related]
[Next] [New Search]